Filter by tags: Iodine-131 Russia Clear all tag filters
16 news articles found
Russia's Ministry of Industry and Trade, representatives from the Kaluga region and the city of Obninsk, and Rosatom have signed a special investment contract for the construction of what Rosatom says will be Europe's largest plant for the production of radiopharmaceuticals.
- Source: World Nuclear News
- Date: Wednesday, 11 October 2023
- Original article: world-nuclear-news.org/Articles/Special-investment-contract-signed-for-Russian-med
International Atomic Energy Agency (IAEA) Director General Rafael Mariano Grossi says IAEA experts present at Ukraine’s Zaporizhia NPP (ZNPP) have in recent days and weeks inspected parts of the facility – including some sections of the perimeter of the large cooling pond – and have also conducted regular walkdowns across the site, so far without observing any visible indications of mines or explosives.
- Source: NEI Magazine
- Date: Friday, 07 July 2023
- Original article: neimagazine.com/news/newsattack-on-zaporizhia-npp-may-have-been-averted-10988247
Russian nuclear utility Rosenergoatom (Electric Power Division of Rosatom) is expanding the range of radioactive isotopes produced at NPPs. In the near future, the production of the radioactive isotope samarium-153 will be launched at the Leningrad NPP. Radiopharmaceuticals based on samarium-153 (Sm-153) are widely used in nuclear medicine to reduce pain in bone metastases to provide palliative care to cancer patients, as well as in traumatology for chronic diseases of the musculoskeletal system.
- Source: NEI Magazine
- Date: Wednesday, 21 June 2023
- Original article: neimagazine.com/news/newsleningrad-npp-to-expand-medical-radioisotope-production-10952159
Production of medical isotopes - iodine-131 (I-131) and molybdenum-99 (Mo-99) is to begin at Russia’s Smolensk and Kursk NPPs following discussions held at Leningrad NPP. Participants included representatives of nuclear utility Rosenergoatom, specialists from the Leningrad, Smolensk and Kursk plants and equipment developers from the NA Dollezhal Scientific Research & Design Institute of Power Engineering (Nikiet).
- Source: NEI Magazine
- Date: Thursday, 15 June 2023
- Original article: neimagazine.com/news/newsrosenergoatom-to-produce-medical-isotopes-at-two-more-npps-10941177
Medical isotopes are radioactive substances used in various diagnostic and therapeutic procedures to treat various types of cancers and other conditions. They are essential for modern medicine, allowing physicians to visualise and target specific organs, tissues and cells in a patient’s body.
Over more than a decade, personalised medicine using nuclear techniques has been gaining pace, allowing doctors to tailor therapies and treatments to the specific needs and physiology of a patient, and to avoid harm to healthy organs or tissues.
According to Sven Van den Berghe, chief executive of Belgium-based isotope producer PanTera, one technique that has seen significant advances is known as theranostics – the term used to describe the combination of using one radioactive drug to diagnose and a second to deliver therapy to treat the main tumour and any metastatic tumours.
- Source: Nucnet
- Date: Friday, 14 April 2023
- Original article: nucnet.org/news/sector-aims-to-tackle-isotope-supply-problems-as-excitement-grows-over-targeted-therapies-4-4-2023
Russia’s Smolensk NPP has sent to Leningrad NPP the first ever batch of cobalt-60 (Co-60) in four containers. Co-60 is used in the production of gamma radiation sources widely employed in medicine, industry and agriculture. The most widely used Co-60 from nuclear utility Rosenergoatom is the production of Co-60 ionising radiation sources for irradiators that sterilise medical devices, food and other products. One such shipment of Co-60 from Smolensk will sterilise at least 30,000 cubic metres of medical products.
- Source: NEI Magazine
- Date: Saturday, 25 February 2023
- Original article: neimagazine.com/news/newsrussias-smolensk-npp-delivers-first-batch-of-cobalt-60-10622665
Rosatom has begun construction of a new plant for the production of medical isotope products at the Karpov Scientific Research Institute of Physics & Chemistry in Obninsk, Kaluga region. The plant will produce a wide range of radiopharmaceuticals including those based on iodine-131, samarium-153, and molybdenum-99 isotopes. It will also develop promising active radiopharmaceuticals based on lutetium-177, actinium-225, radium-223 and other isotopes. Once completed, in 2025, it will be the largest such facility in Europe, Rosatom says. It will operate in accordance with international GMP (good manufacturing practice) standards.
- Source: NEI Magazine
- Date: Friday, 27 January 2023
- Original article: neimagazine.com/news/newsrosatom-begins-construction-of-radiopharmaceuticals-plant-10546229
The aim is to have production lines operating at the plant in Obninsk by 2025, supplying products for the diagnosis and treatment of patients, including a wide range of cancers. Rosatom says it will ensure Russia's sovereignty in the production of radiopharmaceuticals.
- Source: World Nuclear News
- Date: Wednesday, 25 January 2023
- Original article: world-nuclear-news.org/Articles/Construction-starts-for-Russian-medical-isotopes-p
Isotop JSC (part of Rusatom Healthcare, Rosatom’s radiation technologies integrator) on 9 June signed a five-year contract with Brazil’s Nuclear and Energy Research Institute (IPEN, part of the National Nuclear Energy Commission, CNEN) to supply medical isotopes lutetium-177 and actinium-225.
- Source: NEI Magazine
- Date: Friday, 11 June 2021
- Original article: neimagazine.com/news/newsrosatom-to-supply-brazil-with-key-medical-isotopes-8810883
Scientists at Russia’s DI Mendeleev University of Chemical Technology (MUCTR) have developed a new technology for the manufacture of a sorbent for the elusive form of radioactive iodine - methyl iodide.
- Source: NEI Magazine
- Date: Thursday, 21 January 2021
- Original article: neimagazine.com/news/newsrussian-scientists-develop-a-supersorbent-for-radioactive-iodine-8462287